Global Prostatic Artery Embolization

Prostatic Artery Embolization Comprehensive Study by Type (Guidewires, Micro catheters, Microspheres), Application (Hospitals, Ambulatory Surgical centers, Specialty clinics) Players and Region - Global Market Outlook to 2026

Prostatic Artery Embolization Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Prostatic Artery Embolization Market Overview:
Prostatic Artery embolization (PAE) is arising as a viable insignificantly obtrusive treatment for lower urinary tract symptoms due to benevolent prostatic hyperplasia. Benevolent prostatic hyperplasia influences over half of the men by the age of 60 years and up to 80% of men more established than 70 years, and its commonness is expanding as the population ages. Lower urinary tract side effects are related to diminished personal life. PAE is a negligibly obtrusive treatment that is safe and viable. PAE is in fact requesting, and fruitful results require gritty information on the kind of prostatic hyperplasia sickness measure, patient assessment, and the pelvic arterial vessel systems. Therefore, Prostatic artery embolization is performed through a small puncture in the groin in which a catheter is inserted through the artery and directed toward the prostate and once the catheter is situated in the vein providing blood to the prostate, little particles have infused that stop up the course, hindering bloodstream.

Growth Drivers
  • Increase awareness about prostate hyperplasia
  • Growing medical advancements in urology-related procedures

Roadblocks
  • Post PAE syndrome is a side effect associated with prostatic arterial embolization
  • High Cost is associated with prostatic artery embolization

Opportunities
  • Formulation of standard rules and regulations by regulatory bodies across the nations
  • Make continuous research and development to reduce side effects after prostatic artery embolization

Challenges
  • Development of research and development infrastructure in emerging countries
  • Cost-effective treatment of prostatic artery embolization


Competitive Landscape:
This industry is fragmented by market-leading players, and those are strongly focusing on developing new methodologies by collaborating with the other company and try to get excellence. With the increase in market opportunities, the organizations are making mergers and acquisitions and availing competitive advantages.
Some of the key players profiled in the report are Merit Medical (United States), Mentice (United States), Boston Scientific (United States), Siemens Healthcare (Germany), UNC Health Care (United States), Tampa General Hospital (United States), Henry Ford Health System (United States) and Spire Healthcare (United Kingdom). Analyst at AMA Research see United States Players to retain maximum share of Global Prostatic Artery Embolization market by 2026.

Latest Market Insights:
On 21 Jan 2021, Boston Scientific announced that it has entered into a definitive agreement to acquire Preventice Solutions, Inc., a privately-held company that offers a full portfolio of mobile cardiac health solutions and services, ranging from ambulatory cardiac monitors – including short and long-term Holter monitors – to cardiac event monitors and mobile cardiac telemetry.

The food and Drug Administration (FDA) is the regulatory authority in the United States is involved in the formulation of different rules and regulations with respect to the utilization of Prostatic Artery Embolization treatment. Also, FDA is the authority that provides guidelines regarding research and development in Prostatic Artery Embolization.

What Can be Explored with the Prostatic Artery Embolization Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Prostatic Artery Embolization Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Prostatic Artery Embolization
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Prostatic Artery Embolization market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Prostatic Artery Embolization market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Pharmaceuticals Companies, Government Regulatory Bodies, Private Research Institutions, Industrial Associations and Government Research Institutions.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Guidewires
  • Micro catheters
  • Microspheres
By Application
  • Hospitals
  • Ambulatory Surgical centers
  • Specialty clinics
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase awareness about prostate hyperplasia
      • 3.2.2. Growing medical advancements in urology-related procedures
    • 3.3. Market Challenges
      • 3.3.1. Development of research and development infrastructure in emerging countries
      • 3.3.2. Cost-effective treatment of prostatic artery embolization
    • 3.4. Market Trends
      • 3.4.1. The minimally invasive technique of prostatic arterial embolization is highly favorable among men
      • 3.4.2. Higher patient access in Prostate artery embolization
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Prostatic Artery Embolization, by Type, Application and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Prostatic Artery Embolization (Value)
      • 5.2.1. Global Prostatic Artery Embolization by: Type (Value)
        • 5.2.1.1. Guidewires
        • 5.2.1.2. Micro catheters
        • 5.2.1.3. Microspheres
      • 5.2.2. Global Prostatic Artery Embolization by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Ambulatory Surgical centers
        • 5.2.2.3. Specialty clinics
      • 5.2.3. Global Prostatic Artery Embolization Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Prostatic Artery Embolization (Price)
      • 5.3.1. Global Prostatic Artery Embolization by: Type (Price)
  • 6. Prostatic Artery Embolization: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merit Medical (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Mentice (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Boston Scientific (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Siemens Healthcare (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. UNC Health Care (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Tampa General Hospital (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Henry Ford Health System (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Spire Healthcare (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Prostatic Artery Embolization Sale, by Type, Application and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Prostatic Artery Embolization (Value)
      • 7.2.1. Global Prostatic Artery Embolization by: Type (Value)
        • 7.2.1.1. Guidewires
        • 7.2.1.2. Micro catheters
        • 7.2.1.3. Microspheres
      • 7.2.2. Global Prostatic Artery Embolization by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Ambulatory Surgical centers
        • 7.2.2.3. Specialty clinics
      • 7.2.3. Global Prostatic Artery Embolization Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Prostatic Artery Embolization (Price)
      • 7.3.1. Global Prostatic Artery Embolization by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Prostatic Artery Embolization: by Type(USD Million)
  • Table 2. Prostatic Artery Embolization Guidewires , by Region USD Million (2015-2020)
  • Table 3. Prostatic Artery Embolization Micro catheters , by Region USD Million (2015-2020)
  • Table 4. Prostatic Artery Embolization Microspheres , by Region USD Million (2015-2020)
  • Table 5. Prostatic Artery Embolization: by Application(USD Million)
  • Table 6. Prostatic Artery Embolization Hospitals , by Region USD Million (2015-2020)
  • Table 7. Prostatic Artery Embolization Ambulatory Surgical centers , by Region USD Million (2015-2020)
  • Table 8. Prostatic Artery Embolization Specialty clinics , by Region USD Million (2015-2020)
  • Table 9. South America Prostatic Artery Embolization, by Country USD Million (2015-2020)
  • Table 10. South America Prostatic Artery Embolization, by Type USD Million (2015-2020)
  • Table 11. South America Prostatic Artery Embolization, by Application USD Million (2015-2020)
  • Table 12. Brazil Prostatic Artery Embolization, by Type USD Million (2015-2020)
  • Table 13. Brazil Prostatic Artery Embolization, by Application USD Million (2015-2020)
  • Table 14. Argentina Prostatic Artery Embolization, by Type USD Million (2015-2020)
  • Table 15. Argentina Prostatic Artery Embolization, by Application USD Million (2015-2020)
  • Table 16. Rest of South America Prostatic Artery Embolization, by Type USD Million (2015-2020)
  • Table 17. Rest of South America Prostatic Artery Embolization, by Application USD Million (2015-2020)
  • Table 18. Asia Pacific Prostatic Artery Embolization, by Country USD Million (2015-2020)
  • Table 19. Asia Pacific Prostatic Artery Embolization, by Type USD Million (2015-2020)
  • Table 20. Asia Pacific Prostatic Artery Embolization, by Application USD Million (2015-2020)
  • Table 21. China Prostatic Artery Embolization, by Type USD Million (2015-2020)
  • Table 22. China Prostatic Artery Embolization, by Application USD Million (2015-2020)
  • Table 23. Japan Prostatic Artery Embolization, by Type USD Million (2015-2020)
  • Table 24. Japan Prostatic Artery Embolization, by Application USD Million (2015-2020)
  • Table 25. India Prostatic Artery Embolization, by Type USD Million (2015-2020)
  • Table 26. India Prostatic Artery Embolization, by Application USD Million (2015-2020)
  • Table 27. South Korea Prostatic Artery Embolization, by Type USD Million (2015-2020)
  • Table 28. South Korea Prostatic Artery Embolization, by Application USD Million (2015-2020)
  • Table 29. Taiwan Prostatic Artery Embolization, by Type USD Million (2015-2020)
  • Table 30. Taiwan Prostatic Artery Embolization, by Application USD Million (2015-2020)
  • Table 31. Australia Prostatic Artery Embolization, by Type USD Million (2015-2020)
  • Table 32. Australia Prostatic Artery Embolization, by Application USD Million (2015-2020)
  • Table 33. Rest of Asia-Pacific Prostatic Artery Embolization, by Type USD Million (2015-2020)
  • Table 34. Rest of Asia-Pacific Prostatic Artery Embolization, by Application USD Million (2015-2020)
  • Table 35. Europe Prostatic Artery Embolization, by Country USD Million (2015-2020)
  • Table 36. Europe Prostatic Artery Embolization, by Type USD Million (2015-2020)
  • Table 37. Europe Prostatic Artery Embolization, by Application USD Million (2015-2020)
  • Table 38. Germany Prostatic Artery Embolization, by Type USD Million (2015-2020)
  • Table 39. Germany Prostatic Artery Embolization, by Application USD Million (2015-2020)
  • Table 40. France Prostatic Artery Embolization, by Type USD Million (2015-2020)
  • Table 41. France Prostatic Artery Embolization, by Application USD Million (2015-2020)
  • Table 42. Italy Prostatic Artery Embolization, by Type USD Million (2015-2020)
  • Table 43. Italy Prostatic Artery Embolization, by Application USD Million (2015-2020)
  • Table 44. United Kingdom Prostatic Artery Embolization, by Type USD Million (2015-2020)
  • Table 45. United Kingdom Prostatic Artery Embolization, by Application USD Million (2015-2020)
  • Table 46. Netherlands Prostatic Artery Embolization, by Type USD Million (2015-2020)
  • Table 47. Netherlands Prostatic Artery Embolization, by Application USD Million (2015-2020)
  • Table 48. Rest of Europe Prostatic Artery Embolization, by Type USD Million (2015-2020)
  • Table 49. Rest of Europe Prostatic Artery Embolization, by Application USD Million (2015-2020)
  • Table 50. MEA Prostatic Artery Embolization, by Country USD Million (2015-2020)
  • Table 51. MEA Prostatic Artery Embolization, by Type USD Million (2015-2020)
  • Table 52. MEA Prostatic Artery Embolization, by Application USD Million (2015-2020)
  • Table 53. Middle East Prostatic Artery Embolization, by Type USD Million (2015-2020)
  • Table 54. Middle East Prostatic Artery Embolization, by Application USD Million (2015-2020)
  • Table 55. Africa Prostatic Artery Embolization, by Type USD Million (2015-2020)
  • Table 56. Africa Prostatic Artery Embolization, by Application USD Million (2015-2020)
  • Table 57. North America Prostatic Artery Embolization, by Country USD Million (2015-2020)
  • Table 58. North America Prostatic Artery Embolization, by Type USD Million (2015-2020)
  • Table 59. North America Prostatic Artery Embolization, by Application USD Million (2015-2020)
  • Table 60. United States Prostatic Artery Embolization, by Type USD Million (2015-2020)
  • Table 61. United States Prostatic Artery Embolization, by Application USD Million (2015-2020)
  • Table 62. Canada Prostatic Artery Embolization, by Type USD Million (2015-2020)
  • Table 63. Canada Prostatic Artery Embolization, by Application USD Million (2015-2020)
  • Table 64. Mexico Prostatic Artery Embolization, by Type USD Million (2015-2020)
  • Table 65. Mexico Prostatic Artery Embolization, by Application USD Million (2015-2020)
  • Table 66. Prostatic Artery Embolization: by Type(USD/Units)
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Prostatic Artery Embolization: by Type(USD Million)
  • Table 76. Prostatic Artery Embolization Guidewires , by Region USD Million (2021-2026)
  • Table 77. Prostatic Artery Embolization Micro catheters , by Region USD Million (2021-2026)
  • Table 78. Prostatic Artery Embolization Microspheres , by Region USD Million (2021-2026)
  • Table 79. Prostatic Artery Embolization: by Application(USD Million)
  • Table 80. Prostatic Artery Embolization Hospitals , by Region USD Million (2021-2026)
  • Table 81. Prostatic Artery Embolization Ambulatory Surgical centers , by Region USD Million (2021-2026)
  • Table 82. Prostatic Artery Embolization Specialty clinics , by Region USD Million (2021-2026)
  • Table 83. South America Prostatic Artery Embolization, by Country USD Million (2021-2026)
  • Table 84. South America Prostatic Artery Embolization, by Type USD Million (2021-2026)
  • Table 85. South America Prostatic Artery Embolization, by Application USD Million (2021-2026)
  • Table 86. Brazil Prostatic Artery Embolization, by Type USD Million (2021-2026)
  • Table 87. Brazil Prostatic Artery Embolization, by Application USD Million (2021-2026)
  • Table 88. Argentina Prostatic Artery Embolization, by Type USD Million (2021-2026)
  • Table 89. Argentina Prostatic Artery Embolization, by Application USD Million (2021-2026)
  • Table 90. Rest of South America Prostatic Artery Embolization, by Type USD Million (2021-2026)
  • Table 91. Rest of South America Prostatic Artery Embolization, by Application USD Million (2021-2026)
  • Table 92. Asia Pacific Prostatic Artery Embolization, by Country USD Million (2021-2026)
  • Table 93. Asia Pacific Prostatic Artery Embolization, by Type USD Million (2021-2026)
  • Table 94. Asia Pacific Prostatic Artery Embolization, by Application USD Million (2021-2026)
  • Table 95. China Prostatic Artery Embolization, by Type USD Million (2021-2026)
  • Table 96. China Prostatic Artery Embolization, by Application USD Million (2021-2026)
  • Table 97. Japan Prostatic Artery Embolization, by Type USD Million (2021-2026)
  • Table 98. Japan Prostatic Artery Embolization, by Application USD Million (2021-2026)
  • Table 99. India Prostatic Artery Embolization, by Type USD Million (2021-2026)
  • Table 100. India Prostatic Artery Embolization, by Application USD Million (2021-2026)
  • Table 101. South Korea Prostatic Artery Embolization, by Type USD Million (2021-2026)
  • Table 102. South Korea Prostatic Artery Embolization, by Application USD Million (2021-2026)
  • Table 103. Taiwan Prostatic Artery Embolization, by Type USD Million (2021-2026)
  • Table 104. Taiwan Prostatic Artery Embolization, by Application USD Million (2021-2026)
  • Table 105. Australia Prostatic Artery Embolization, by Type USD Million (2021-2026)
  • Table 106. Australia Prostatic Artery Embolization, by Application USD Million (2021-2026)
  • Table 107. Rest of Asia-Pacific Prostatic Artery Embolization, by Type USD Million (2021-2026)
  • Table 108. Rest of Asia-Pacific Prostatic Artery Embolization, by Application USD Million (2021-2026)
  • Table 109. Europe Prostatic Artery Embolization, by Country USD Million (2021-2026)
  • Table 110. Europe Prostatic Artery Embolization, by Type USD Million (2021-2026)
  • Table 111. Europe Prostatic Artery Embolization, by Application USD Million (2021-2026)
  • Table 112. Germany Prostatic Artery Embolization, by Type USD Million (2021-2026)
  • Table 113. Germany Prostatic Artery Embolization, by Application USD Million (2021-2026)
  • Table 114. France Prostatic Artery Embolization, by Type USD Million (2021-2026)
  • Table 115. France Prostatic Artery Embolization, by Application USD Million (2021-2026)
  • Table 116. Italy Prostatic Artery Embolization, by Type USD Million (2021-2026)
  • Table 117. Italy Prostatic Artery Embolization, by Application USD Million (2021-2026)
  • Table 118. United Kingdom Prostatic Artery Embolization, by Type USD Million (2021-2026)
  • Table 119. United Kingdom Prostatic Artery Embolization, by Application USD Million (2021-2026)
  • Table 120. Netherlands Prostatic Artery Embolization, by Type USD Million (2021-2026)
  • Table 121. Netherlands Prostatic Artery Embolization, by Application USD Million (2021-2026)
  • Table 122. Rest of Europe Prostatic Artery Embolization, by Type USD Million (2021-2026)
  • Table 123. Rest of Europe Prostatic Artery Embolization, by Application USD Million (2021-2026)
  • Table 124. MEA Prostatic Artery Embolization, by Country USD Million (2021-2026)
  • Table 125. MEA Prostatic Artery Embolization, by Type USD Million (2021-2026)
  • Table 126. MEA Prostatic Artery Embolization, by Application USD Million (2021-2026)
  • Table 127. Middle East Prostatic Artery Embolization, by Type USD Million (2021-2026)
  • Table 128. Middle East Prostatic Artery Embolization, by Application USD Million (2021-2026)
  • Table 129. Africa Prostatic Artery Embolization, by Type USD Million (2021-2026)
  • Table 130. Africa Prostatic Artery Embolization, by Application USD Million (2021-2026)
  • Table 131. North America Prostatic Artery Embolization, by Country USD Million (2021-2026)
  • Table 132. North America Prostatic Artery Embolization, by Type USD Million (2021-2026)
  • Table 133. North America Prostatic Artery Embolization, by Application USD Million (2021-2026)
  • Table 134. United States Prostatic Artery Embolization, by Type USD Million (2021-2026)
  • Table 135. United States Prostatic Artery Embolization, by Application USD Million (2021-2026)
  • Table 136. Canada Prostatic Artery Embolization, by Type USD Million (2021-2026)
  • Table 137. Canada Prostatic Artery Embolization, by Application USD Million (2021-2026)
  • Table 138. Mexico Prostatic Artery Embolization, by Type USD Million (2021-2026)
  • Table 139. Mexico Prostatic Artery Embolization, by Application USD Million (2021-2026)
  • Table 140. Prostatic Artery Embolization: by Type(USD/Units)
  • Table 141. Research Programs/Design for This Report
  • Table 142. Key Data Information from Secondary Sources
  • Table 143. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Prostatic Artery Embolization: by Type USD Million (2015-2020)
  • Figure 5. Global Prostatic Artery Embolization: by Application USD Million (2015-2020)
  • Figure 6. South America Prostatic Artery Embolization Share (%), by Country
  • Figure 7. Asia Pacific Prostatic Artery Embolization Share (%), by Country
  • Figure 8. Europe Prostatic Artery Embolization Share (%), by Country
  • Figure 9. MEA Prostatic Artery Embolization Share (%), by Country
  • Figure 10. North America Prostatic Artery Embolization Share (%), by Country
  • Figure 11. Global Prostatic Artery Embolization: by Type USD/Units (2015-2020)
  • Figure 12. Global Prostatic Artery Embolization share by Players 2020 (%)
  • Figure 13. Global Prostatic Artery Embolization share by Players (Top 3) 2020(%)
  • Figure 14. Global Prostatic Artery Embolization share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Merit Medical (United States) Revenue, Net Income and Gross profit
  • Figure 17. Merit Medical (United States) Revenue: by Geography 2020
  • Figure 18. Mentice (United States) Revenue, Net Income and Gross profit
  • Figure 19. Mentice (United States) Revenue: by Geography 2020
  • Figure 20. Boston Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 21. Boston Scientific (United States) Revenue: by Geography 2020
  • Figure 22. Siemens Healthcare (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Siemens Healthcare (Germany) Revenue: by Geography 2020
  • Figure 24. UNC Health Care (United States) Revenue, Net Income and Gross profit
  • Figure 25. UNC Health Care (United States) Revenue: by Geography 2020
  • Figure 26. Tampa General Hospital (United States) Revenue, Net Income and Gross profit
  • Figure 27. Tampa General Hospital (United States) Revenue: by Geography 2020
  • Figure 28. Henry Ford Health System (United States) Revenue, Net Income and Gross profit
  • Figure 29. Henry Ford Health System (United States) Revenue: by Geography 2020
  • Figure 30. Spire Healthcare (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. Spire Healthcare (United Kingdom) Revenue: by Geography 2020
  • Figure 32. Global Prostatic Artery Embolization: by Type USD Million (2021-2026)
  • Figure 33. Global Prostatic Artery Embolization: by Application USD Million (2021-2026)
  • Figure 34. South America Prostatic Artery Embolization Share (%), by Country
  • Figure 35. Asia Pacific Prostatic Artery Embolization Share (%), by Country
  • Figure 36. Europe Prostatic Artery Embolization Share (%), by Country
  • Figure 37. MEA Prostatic Artery Embolization Share (%), by Country
  • Figure 38. North America Prostatic Artery Embolization Share (%), by Country
  • Figure 39. Global Prostatic Artery Embolization: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Merit Medical (United States)
  • Mentice (United States)
  • Boston Scientific (United States)
  • Siemens Healthcare (Germany)
  • UNC Health Care (United States)
  • Tampa General Hospital (United States)
  • Henry Ford Health System (United States)
  • Spire Healthcare (United Kingdom)
Select User Access Type

Key Highlights of Report


Aug 2021 239 Pages 59 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Prostatic Artery Embolization Quantitative research analysis
Global Prostatic Artery Embolization Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Prostatic Artery Embolization market is expected to see a CAGR of % during projected year 2020 to 2026.
Top performing companies in the Global Prostatic Artery Embolization market are Merit Medical (United States), Mentice (United States), Boston Scientific (United States), Siemens Healthcare (Germany), UNC Health Care (United States), Tampa General Hospital (United States), Henry Ford Health System (United States) and Spire Healthcare (United Kingdom), to name a few.
"The minimally invasive technique of prostatic arterial embolization is highly favorable among men " is seen as one of major influencing trends for Prostatic Artery Embolization Market during projected period 2020-2026.

Know More About Global Prostatic Artery Embolization Report?

Have a Query? Click Here

Other Related Reports

Companion Animal Diagnostics Comprehensive Study by Type (Clinical Biochemistry {Clinical Chemistry Analysis, Glucose Monitoring, Blood Glucose Strips}, Immunodiagnostics {Lateral Flow Assays, ELISA ...
$ 3750
Urinary Tract Infection Treatment Comprehensive Study by Disease Type (Cystitis, Urethritis, Pyelonephritis, Vaginitis), Drug (Azoles, Quinolones, Penicillin and combinations, Aminoglycosides, Cepha...
$ 3800
Breast Cancer Treatment Comprehensive Study by Type (Chemotherapy, Radiation Therapy, Biologic Targeted Therapy, Breast Surgery, Hormone Therapy), Application (Hospitals, Clinics, Pharmacy, Cancer Ce...
$ 3800
Whole Cell Cholera Vaccine Comprehensive Study by Application (Clinical Research Institutes, Hospital, Surgical Centers, Others), End User (For Adults, For Children) Players and Region - Global Marke...
$ 3500
Canine Flu Therapeutics Comprehensive Study by Application (Vet Clinics, Veterinary Hospitals, Animal Healthcare Facilities), Treatment Type (Vaccines, Anti-inflammatory Drugs, Antibiotics, Others) P...
$ 3500
Microbubbles/Ultrasound Contrast Agents Comprehensive Study by Type (Cardiovascular Diseases, Renal Diseases, Others), Application (Molecular Imaging, Gene Therapy, Drug Delivery, Stem Cells Delivery...
$ 3500